PHASE I CLINICAL TRIAL EVALUATING THE SAFETY OF ADP-A2M10 IN PATIENTS WITH MAGE-A10+ HEAD AND NECK, MELANOMA, OR UROTHELIAL TUMORS

被引：2

作者：

Hong, David ^{[1
]}

Butler, Marcus ^{[2
]}

Pachynski, Russell ^{[3
]}

Sullivan, Ryan ^{[4
]}

Kebriaei, Partow ^{[1
]}

Boross-Harmer, Sarah ^{[2
]}

Frigault, Matthew ^{[5
]}

Dumbrava, Ecaterina ^{[1
]}

Sauer, Amy ^{[6
]}

Brophy, Francine ^{[6
]}

Navenot, Jean-Marc ^{[6
]}

Fayngerts, Svetlana ^{[6
]}

Bai, Jane ^{[6
]}

Norry, Elliot ^{[6
]}

Fracasso, Paula ^{[6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Massachusetts Gen Hosp, Somerville, MA USA

[6] Adaptimmune, Philadelphia, PA USA

来源：

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

285

引用

页码：A174 / A174

页数：1